Maximising the Taste and Health Value of Plant Food Products (MAXVEG)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Aarhus University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Aarhus University Hospital
ClinicalTrials.gov Identifier:
NCT01397942
First received: July 18, 2011
Last updated: July 19, 2011
Last verified: May 2011

July 18, 2011
July 19, 2011
May 2011
December 2012   (final data collection date for primary outcome measure)
Insulin sensitivity [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Measured as the iAUC from an Oral Glucose Tolerance Test
Same as current
Complete list of historical versions of study NCT01397942 on ClinicalTrials.gov Archive Site
Urine and blood samples [ Time Frame: 2 years ] [ Designated as safety issue: No ]

The fasting blood samples will be analyzed for: glucose, insulin, glucagon, HbA1c, lipids (triglycerides, HDL-, LDL- and total cholesterol), cytokines (, adipokines biomarkers of oxidative stress parathyroid hormone, vitamin D and GLP-1.

Urine samples for metabolomics (isoprostanes and water-soluble metabolites).

Same as current
Not Provided
Not Provided
 
Maximising the Taste and Health Value of Plant Food Products
Maximising the Taste and Health Value of Plant Food Products - Impact on Vegetable Consumption, Consumer Preferences and Human Health Factors.

To investigate if a high dietary intake of bitter and strong tasting vegetables have positive health effects (insulin sensitivity, glucose tolerance, central obesity, fasting and postprandial lipid profile, blood pressure, vitamin D status and inflammatory markers, biomarkers of oxidative stress) on subjects with T2D, when compared to a high dietary intake of mild and sweet modern vegetables or a normal western diet.

The metabolic syndrome (MS), type 2 diabetes (T2D) and obesity are the world's most prevalent lifestyle diseases. This unfortunate development is mainly caused by lifestyle choices leading to obesity due to physical inactivity and excessive calorie intake.

Vegetables are an important part of the human diet and a major source of biologically active substances which determine the nutritional quality of food, color, taste, smell, antioxidative, anticarcinogenic, antihypertensive, anti-inflammatory, antihyperglycemia, immunostimulating and cholesterol-lowering properties.

Diet, as one aspect of lifestyle, is thought to be one of the modifiable variable risk factors for the development of MS and T2D, but more information is needed as to which components of the diet could be protective for the development and progression of MS and T2D with all its complications.

The study will be carried out as a 3-month randomized controlled parallel intervention study involving 60 subjects with T2D. During the fall year 2011 30 (10 in each group) subjects will participate and the remaining 30 subjects (10 in each group) in the fall 2012. The subjects will be randomized into 3 different diets:

  1. A) "A healthy Nordic diet" with high content of bitter strong tasting vegetables and cabbages.
  2. B) "A healthy Nordic diet" with high content of sweet and mild tasting vegetables and cabbages.
  3. C) A diet habitually consumed in the Nordic countries (normal control diet). The subjects in groups A and B will each have to consume 500 g root vegetables and cabbages daily which will be handed out once a week. The participants will visit the study clinic at screening, and then once weekly during the intervention period (12 weeks). Beside the screening examination there will be 3 major visits (0, 6 and 12 weeks) where the participants will collect urine samples, complete a 3-day weighed food diary (to control diet intake) and undergo clinical examination incl. measuring of blood pressure, body composition and collection of fasting blood samples i.e. glucose, insulin, glucagon, HbA1c, GLP-1, lipids (triglycerides, HDL-, LDL- and total cholesterol), cytokines, adipokines, parathyroid hormone and vitamin D. During first (week 0) and third (week 12) major visit a 120 minutes oral glucose tolerance test is included collecting blood to analyze for glucose, insulin and triglycerides.

The study will contribute to the understanding on the impact of a diet with a high level of root vegetables and cabbages with either high or low levels of phytochemicals. Furthermore, the results can be used to develop new recommendations targeted T2D and MS subjects, and thereby contribute to a healthier lifestyle and to prevent any further development and progression of these lifestyle diseases. The overall perspective of the MAXVEG project is to enhance the consumption and production of bitter and strong tasting health promoting root vegetables and cabbages with high phytochemical content and high consumer preferences targeted specific consumer groups

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Type 2 Diabetes
Other: Diet intervention
The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
Other Names:
  • Vegetables
  • Ancient
  • Cabbages
  • Type 2 diabetes
  • Experimental: Ancient vegatables
    A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
    Intervention: Other: Diet intervention
  • No Intervention: Control Nordic diet
    A diet habitually consumed in the Nordic countries
  • Experimental: Modern Vegetables
    A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
    Intervention: Other: Diet intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
January 2014
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetes in diet treatment or on oral anti-diabetic drug or the metabolic syndrome.

Exclusion Criteria:

  • Other severe diseases or in treatment with insulin, GLP-1 analogs, glitazones.
Both
30 Years to 70 Years
No
Contact: Per B Jeppesen, Prof., PhD +45 22896616 per.bendix.jeppesen@ki.au.dk
Contact: Anne C Thorup, M.Sc, Phd +45 22896616 anne.cathrine.thorup@ki.au.dk
Denmark
 
NCT01397942
09-067129
Yes
Per Bendix Jeppesen, Associate Prof., PhD., Aarhus University Hospital
Aarhus University Hospital
Not Provided
Principal Investigator: Per B Jeppesen, Prof. PhD University of Aarhus
Aarhus University Hospital
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP